A pegylated growth hormone receptor antagonist, pegvisomant, does not enter the brain in humans

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 8, 2010, Pages 3844-3847

  Veldhuis, Johannes D ^a   Bidlingmaier, Martin ^b   Bailey, Joy ^a   Erickson, Dana ^a   Sandroni, Paola ^a  

^a MAYO CLINIC   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; PEGVISOMANT; SOMATOMEDIN;

ADULT; AGED; ARTICLE; ASSAY; ATAXIA; BLOOD BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EXAMINATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HORMONE ACTION; HORMONE RELEASE; HUMAN; MALE; MEDIAN EMINENCE; MUTATION; NEUROPATHY; PRIORITY JOURNAL; SYNCOPE; TERTIARY HEALTH CARE;

EID: 77955357712     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0538     Document Type: Article

References (21)

1. Veldhuis JD, Roemmich JN, Richmond EJ, Bowers CY 2006 Somatotropic and gonadotropic axes linkages in infancy, childhood, and the puberty-adult transition. Endocr Rev 27:101-140
2. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G 2006 Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467-477
3. Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA, Sharma A 2007 Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res 13:1000-1009
4. Lindberg-Larsen R, Møller N, Schmitz O, Nielsen S, Andersen M, Orskov H, Jørgensen JO 2007 The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 92:1724-1728
5. Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ 2001 Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. J Clin Endocrinol Metab 86:3304-3310
6. Veldhuis JD, Bidlingmaier M, Anderson SM, Evans WS, Wu Z, Strasburger CJ 2002 Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. J Clin Endocrinol Metab 87:5737-5745
7. Veldhuis JD, Keenan DM, Bailey JN, Adeniji A, Miles JM, Paulo R, Cosma M, Soares-Welch C 2008 Estradiol supplementation in postmenopausal women attenuates suppression of pulsatile growth-hormone secretion by recombinant human insulin-like growth factor type I. J Clin Endocrinol Metab 93:4471-4478
8. Pan W, Yu Y, Cain CM, Nyberg F, Couraud PO, Kastin AJ 2005 Permeation of growth hormone across the blood-brain barrier. Endocrinology 146:4898-4904
9. Coculescu M 1999 Blood-brain barrier for human growth hormone and insulin-like growth factor-I. J Pediatr Endocrinol Metab 12:113-124
10. Aberg D 2010 Role of the growth hormone/insulin-like growth factor 1 axis in neurogenesis. Endocr Dev 17:63-76
11. Jaeger LB, Banks WA, Varga JL, Schally AV 2005 Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors. Proc Natl Acad Sci USA 102:12495-12500
12. Scheepens A, Williams CE, Breier BH, Guan J, Gluckman PD 2000 A role for the somatotropic axis in neural development, injury and disease. J Pediatr Endocrinol Metab 13(Suppl 6):1483-1491
13. Schneider HJ, Pagotto U, Stalla GK 2003 Central effects of the somatotropic system. Eur J Endocrinol 149:377-392
14. Creyghton WM, van Dam PS, Koppeschaar HP 2004 The role of the somatotropic system in cognition and other cerebral functions. Semin Vasc Med 4:167-172
15. Wiren L, Bengtsson BA, Johannsson G 1998 Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency. Clin Endocrinol (Oxf) 48:613-620
16. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ 2002 Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623-646
17. Schwartz MW, Bergman RN, Kahn SE, Taborsky Jr GJ, Fisher LD, Sipols AJ, Woods SC, Steil GM, Porte Jr D 1991 Evidence for entry of plasma insulin into cerebrospinal fluid through an intermediate compartment in dogs. Quantitative aspects and implications for transport. J Clin Invest 88:1272-1281
18. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med342:1171-1177 (Pubitemid 30211048)
19. Veldhuis JD, Keenan DM, Bowers CY 2007 Estimation of the size and shape of GH secretory bursts in healthy women using a physiological estradiol clamp and variable-waveform deconvolution model. Am J Physiol Regul Integr Comp 293:R1013-R1021
20. Strasburger CJ, Kohen F 1990 Two-site and competitive chemiluminescent immunoassays. Methods Enzymol 184:481-496
21. Hartman ML, Pincus SM, Johnson ML, Matthews DH, Faunt LM, Vance ML, Thorner MO, Veldhuis JD 1994 Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release. J Clin Invest 94:1277-1288